Syndax to Join Goldman Sachs 45th Annual Global Healthcare Conference

Syndax Pharmaceuticals, a prominent clinical-stage biopharmaceutical company based in Waltham, Massachusetts, has announced that its Chief Executive Officer, Michael A. Metzger, will be participating in a fireside chat. This event will take place at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 8:40 a.m. ET.

For those interested in viewing the discussion, a live webcast will be available through the Investor section of Syndax's official website. Additionally, a replay of the chat will be accessible for a limited time on the same platform, allowing stakeholders and interested parties to stay informed about the company's latest developments and strategic direction.

Syndax Pharmaceuticals focuses on creating groundbreaking cancer therapies. Among the key components of its pipeline are revumenib and axatilimab. Revumenib is a highly selective menin inhibitor, while axatilimab is a monoclonal antibody designed to block the CSF-1 receptor, both of which are integral to Syndax's innovative approach to cancer treatment.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!